Brendan Kim Email

Commercial Development Analyst . Sage Therapeutics

Current Roles

Employees:
937
Revenue:
$97.7M
About
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Sage Therapeutics Address
215 First Street
Cambridge, MA
United States

Past Companies

Sage TherapeuticsMarket Access Analyst
Sage TherapeuticsMarket Access Intern
CapTel Service SpecialistsCaptioning Assistant/Coach